Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C N Harrison

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
International Journal of Laboratory Hematology|April 15, 2009
British Society for Haematology, slide session, annual scientific meeting, Glasgow, 2008C V Hutchinson, J Burthem, M Bisland, et al.
Leukemia|March 2, 2017
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosisC N Harrison, A M Vannucchi, J-J Kiladjian, et al.
Leukemia|May 24, 2016
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosisC N Harrison, A M Vannucchi, J-J Kiladjian, et al.
Leukemia|July 18, 2013
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) studyJ V Jovanovic, A Ivey, A M Vannucchi, et al.
The New England Journal of Medicine|December 12, 2013
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2J Nangalia, C E Massie, E J Baxter, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
International Journal of Laboratory Hematology|April 15, 2009
British Society for Haematology, slide session, annual scientific meeting, Glasgow, 2008C V Hutchinson, J Burthem, M Bisland, et al.
Leukemia|March 2, 2017
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosisC N Harrison, A M Vannucchi, J-J Kiladjian, et al.
Leukemia|May 24, 2016
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosisC N Harrison, A M Vannucchi, J-J Kiladjian, et al.
Leukemia|July 18, 2013
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) studyJ V Jovanovic, A Ivey, A M Vannucchi, et al.
The New England Journal of Medicine|December 12, 2013
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2J Nangalia, C E Massie, E J Baxter, et al.
Pageof 3